Find the Perfect Plan for Your Investment Journey
H
Latest price
52 Week Range
€1.18 - €1.88
Next Earnings Date
-
Next Earnings Date
-
Latest price
Market Cap | €33.85M |
EV | €31.79M |
Shares Outstanding | 24.09M |
Beta | 0.38 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | €1.90 |
P/E 2024E | - |
P/Revenue 2024E | - |
Revenue | - |
EPS | - |
Operating Cash Flow | 18.50% |
Free Cash Flow | 18.50% |
Revenue | - |
EPS | - |
Operating Cash Flow | -1.20% |
Free Cash Flow | -1.20% |
Gross Margin 2024E | - |
Net Profit Margin 2024E | - |
ROE 2024E | - |
ROCE 2023 | 11.99% |
DPS 2024E | - |
Payout Ratio 2024E | - |
Div. Yield 2024E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
H
Herantis Pharma Oyj
HRTIS
Sector
Healthcare
Industry
Biotechnology
CEO
Vuolanto, Antti
Employees
11
Website
herantis.comIPO Date
2014-06-11
Headquarters
Bertel Jungin Aukio 1, Espoo, Uusimaa, 02600, Finland
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved